As we previously reported in ALK-positive patient CTCs at resistance to ALK inhibitors [26], we observed here that several alterations may occur within a single CTC in BRAFV600E NSCLC at therapeutic resistance. This evidence concerns the gene ALK and non-small cell lung carcinoma.